Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Open in Screener

MAZE

Maze Therapeutics Inc

Jan 09 • 04:00PM ET

40.32

+1.37 3.52 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IBB IWN SCHA XPH VTWO DWAS IHE

Index	RUT	P/E	-	EPS (ttm)	-2.25	Insider Own	45.74%	Shs Outstand	48.08M	Perf Week	1.38%
Market Cap	1.94B	Forward P/E	-	EPS next Y	-3.15	Insider Trans	-0.98%	Shs Float	26.11M	Perf Month	-1.08%
Enterprise Value	1.58B	PEG	-	EPS next Q	-0.71	Inst Own	42.18%	Short Float	8.52%	Perf Quarter	40.19%
Income	-101.46M	P/S	-	EPS this Y	-350.43%	Inst Trans	13.04%	Short Ratio	5.60	Perf Half Y	167.91%
Sales	0.00M	P/B	5.11	EPS next Y	-0.60%	ROA	-28.15%	Short Interest	2.22M	Perf YTD	-2.68%
Book/sh	7.89	P/C	5.05	EPS next 5Y	-	ROE	-36.13%	52W High	43.29 -6.86%	Perf Year	-
Cash/sh	7.98	P/FCF	-	EPS past 3/5Y	- -	ROIC	-25.44%	52W Low	6.71 500.89%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.27% 5.17%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.63	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	17.70	EPS Q/Q	-1029.60%	SMA20	0.03%	Beta	4.54	Target Price	48.67
Payout	-	Debt/Eq	0.06	Sales Q/Q	-100.00%	SMA50	8.27%	Rel Volume	0.52	Prev Close	38.95
Employees	125	LT Debt/Eq	0.05	Earnings	Nov 06 AMC	SMA200	91.73%	Avg Volume	397.17K	Price	40.32
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.81% -	Trades		Volume	204,850	Change	3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Initiated	Wells Fargo	Overweight	$55
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy	$30
Jul-23-25	Initiated	H.C. Wainwright	Buy	$34
Jul-08-25	Initiated	Wedbush	Outperform	$17

Jan-05-26 07:00AM	Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-06-25 04:01PM	Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
07:00AM	Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week (GlobeNewswire)
Nov-04-25 07:00AM	Maze Therapeutics to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
Oct-28-25 04:43PM	Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease (CNBC TV)
07:00AM	Loading…
Oct-06-25 07:00AM	Maze Therapeutics Appoints Industry Veteran Herve Hoppenot as Chairman of the Board of Directors (GlobeNewswire)
Sep-19-25 04:02PM	Maze Therapeutics, Inc. (MAZE): A Bull Case Theory (Insider Monkey)
Sep-17-25 06:22PM	Biotech Breakouts: 3 Stocks With Massive Upside Potential (MarketBeat)
Sep-12-25 07:45AM	Maze reports positive results from Phase I trial of PKU and CKD treatment (Clinical Trials Arena) -6.07%
06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive)
Sep-11-25 09:29AM	Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results (Investor's Business Daily) +54.81%
07:35AM	Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement (GlobeNewswire)
07:30AM	Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) (GlobeNewswire)
Sep-02-25 07:00AM	Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer (GlobeNewswire) +5.73%
Aug-12-25 04:01PM	Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
07:46AM	Loading…
Jul-31-25 07:46AM	Venture firm Frazier closes $1.3B fund for early-stage biotech investing (BioPharma Dive)
Jul-10-25 04:05PM	Maze Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-29-25 07:30AM	Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +6.01%
May-14-25 04:01PM	Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones (GlobeNewswire) -8.11%
May-13-25 07:30AM	Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Mar-31-25 07:30AM	Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-26-25 05:02PM	Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (SeekingAlpha) -7.48%
Feb-25-25 04:11PM	Maze Therapeutics receives positive ratings following recent IPO (Investing.com) +10.69%
Feb-10-25 07:09AM	Maze Therapeutics doses first subject in Phase II AKD treatment trial (Clinical Trials Arena)
Feb-07-25 08:00AM	Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
07:30PM	Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bernstein Harold	President, R&D & CMO	Jan 07 '26	Option Exercise	10.42	25,156	262,126	25,156	Jan 09 04:51 PM
Bernstein Harold	President, R&D & CMO	Jan 07 '26	Sale	40.20	25,156	1,011,299	0	Jan 09 04:51 PM
Sohn Catherine A.	Director	Jan 07 '26	Option Exercise	10.42	26,920	280,506	26,920	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 06 '26	Option Exercise	10.42	2,493	25,977	2,493	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 07 '26	Sale	39.11	26,920	1,052,785	0	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 06 '26	Sale	38.62	2,493	96,270	0	Jan 08 04:30 PM
CATHERINE SOHN	Director	Jan 07 '26	Proposed Sale	39.11	26,920	1,052,785		Jan 07 04:00 PM
CATHERINE SOHN	Director	Jan 06 '26	Proposed Sale	38.62	2,493	96,270		Jan 06 04:36 PM
Bernstein Harold	President, R&D & CMO	Jan 02 '26	Option Exercise	10.42	4,432	46,181	4,432	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 05 '26	Option Exercise	10.42	412	4,293	412	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 02 '26	Sale	40.43	4,432	179,188	0	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 05 '26	Sale	40.00	412	16,480	0	Jan 06 04:31 PM
Bachrodt Amy	SVP, Finance	Jan 02 '26	Option Exercise	10.42	5,000	52,100	17,965	Jan 06 04:30 PM
Bachrodt Amy	SVP, Finance	Jan 02 '26	Sale	39.15	5,000	195,754	12,965	Jan 06 04:30 PM
Dandekar Atul	CSBO	Dec 29 '25	Option Exercise	10.42	72,400	754,408	82,903	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 30 '25	Option Exercise	10.42	100	1,042	10,603	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 29 '25	Sale	40.56	72,400	2,936,763	10,503	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 30 '25	Sale	40.36	100	4,036	10,503	Dec 31 04:24 PM
Bernstein Harold	President, R&D & CMO	Dec 29 '25	Option Exercise	10.42	45,000	468,900	45,000	Dec 31 04:22 PM
Bernstein Harold	President, R&D & CMO	Dec 29 '25	Sale	40.56	45,000	1,825,355	0	Dec 31 04:22 PM
Bachrodt Amy	SVP, Finance	Dec 29 '25	Option Exercise	10.42	10,000	104,200	22,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 30 '25	Option Exercise	10.42	5,000	52,100	17,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 29 '25	Sale	40.58	10,000	405,766	12,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 30 '25	Sale	40.08	5,000	200,407	12,965	Dec 31 04:20 PM
HAROLD BERNSTEIN	Officer	Dec 29 '25	Proposed Sale	42.10	105,000	4,420,500		Dec 29 04:28 PM
ATUL P DANDEKAR	Officer	Dec 29 '25	Proposed Sale	42.10	87,500	3,683,750		Dec 29 04:25 PM
SEKAR KATHIRESAN	Former Board Member	Dec 04 '25	Proposed Sale	42.54	10,000	425,423		Dec 04 04:08 PM
SEKAR KATHIRESAN	Former Board Member	Nov 21 '25	Proposed Sale	35.80	27,500	984,588		Nov 21 04:09 PM
SCHELLER RICHARD H	Director	Sep 15 '25	Sale	22.37	20,744	464,035	0	Sep 16 04:26 PM
RICHARD SCHELLER	Director	Sep 15 '25	Proposed Sale	22.37	20,744	464,035		Sep 15 04:07 PM

Open in Screener

ALT

Altimmune Inc

Jan 09 • 04:00PM ET

4.02

-0.06 -1.47 %

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: XBI VTI IWM VXF IWO IBB VTWO FESM VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	0.71%	Shs Outstand	104.34M	Perf Week	14.53%
Market Cap	419.46M	Forward P/E	-	EPS next Y	-1.23	Insider Trans	4.30%	Shs Float	103.60M	Perf Month	-27.17%
Enterprise Value	224.54M	PEG	-	EPS next Q	-0.24	Inst Own	40.01%	Short Float	22.89%	Perf Quarter	0.50%
Income	-83.92M	P/S	20972.97	EPS this Y	27.05%	Inst Trans	3.96%	Short Ratio	5.82	Perf Half Y	-2.90%
Sales	0.02M	P/B	2.07	EPS next Y	-25.83%	ROA	-45.82%	Short Interest	23.72M	Perf YTD	11.36%
Book/sh	1.94	P/C	1.99	EPS next 5Y	9.04%	ROE	-52.61%	52W High	7.73 -47.99%	Perf Year	-45.01%
Cash/sh	2.02	P/FCF	-	EPS past 3/5Y	17.12% 3.48%	ROIC	-41.70%	52W Low	2.90 38.62%	Perf 3Y	-72.86%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-83.45% -67.83%	Gross Margin	-495.00%	Volatility	8.41% 7.31%	Perf 5Y	-68.37%
Dividend TTM	-	EV/Sales	11226.97	EPS Y/Y TTM	31.25%	Oper. Margin	-452310.00%	ATR (14)	0.34	Perf 10Y	-94.03%
Dividend Ex-Date	-	Quick Ratio	17.18	Sales Y/Y TTM	-61.54%	Profit Margin	-419575.00%	RSI (14)	44.28	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	17.18	EPS Q/Q	33.85%	SMA20	-6.17%	Beta	0.08	Target Price	20.14
Payout	-	Debt/Eq	0.09	Sales Q/Q	0.00%	SMA50	-10.12%	Rel Volume	0.75	Prev Close	4.08
Employees	59	LT Debt/Eq	0.08	Earnings	Nov 06 BMO	SMA200	-11.35%	Avg Volume	4.08M	Price	4.02
IPO	Oct 06, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.82% 257.14%	Trades		Volume	3,045,957	Change	-1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Sell	$1
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30
Oct-09-17	Initiated	Piper Jaffray	Overweight	$6

Show Previous Ratings

Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Jan-05-26 07:30AM	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH (GlobeNewswire) +16.52%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
Dec-19-25 06:30AM	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial (GlobeNewswire) -22.77%
Dec-11-25 09:55AM	Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? (Zacks)
07:30AM	Loading…
Dec-01-25 07:30AM	Altimmune Announces CEO Transition and Succession Plan (GlobeNewswire) -6.27%
Nov-26-25 07:30AM	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-25-25 09:55AM	Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know (Zacks)
Nov-11-25 08:51AM	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-08-25 06:05AM	Altimmune price target lowered to $14 from $15 at Citizens JMP (TipRanks)
Nov-07-25 08:05AM	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 07:00AM	Altimmune Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) +5.07%
Nov-05-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder (GlobeNewswire)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
07:30AM	Loading…
Oct-30-25 07:30AM	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 (GlobeNewswire)
Oct-20-25 07:30AM	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 08:45AM	Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Sep-30-25 10:52AM	Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALT (Business Wire)
Sep-29-25 07:30AM	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide (GlobeNewswire) -5.25%
Sep-23-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 07:30AM	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer (GlobeNewswire)
Sep-09-25 09:00AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire)
Sep-02-25 08:45AM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Aug-26-25 08:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
07:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-25 07:30AM	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
Aug-14-25 04:34PM	Investors in Altimmune, Inc. (ALT): Protect Your Rights - Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
Aug-13-25 04:24PM	Altimmune, Inc. (ALT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
03:07AM	Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... (GuruFocus.com)
07:00AM	Loading…
Aug-12-25 07:00AM	Altimmune Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) +7.10%
Aug-11-25 07:30AM	Altimmune Board of Directors Appoints Jerry Durso as Chairman (GlobeNewswire)
Aug-05-25 07:30AM	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 (GlobeNewswire)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-09-25 07:30AM	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) (GlobeNewswire)
01:19AM	Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial (Insider Monkey)
Jun-26-25 07:00AM	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH (GlobeNewswire) -53.18%
Jun-25-25 07:12PM	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 (GlobeNewswire) +7.23%
Jun-18-25 09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
Jun-13-25 07:30AM	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
May-21-25 11:17AM	Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential (Insider Monkey)
May-19-25 07:30AM	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks)
07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-13-25 07:00AM	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital (GlobeNewswire)
07:00AM	Altimmune Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 01:01PM	Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? (Zacks) +7.51%
06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-09-25 09:55AM	How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% (Zacks)
May-08-25 07:30AM	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress (GlobeNewswire) +8.21%
May-06-25 07:30AM	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (GlobeNewswire) -7.37%
May-01-25 07:30AM	Altimmune to Present at Upcoming EASL International Liver Congress 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Altimmune to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -15.59%
07:30AM	Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt (GlobeNewswire)
Jun-24-24 06:02PM	Crypto under pressure, Good Buy or Goodbye: Market Domination (Yahoo Finance Video) +11.39%
03:52PM	Altimmune reports positive results in weight-loss drug trial (Yahoo Finance Video)
11:13AM	BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms (InvestorPlace)
10:56AM	ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings (InvestorPlace)
Jun-23-24 01:45PM	Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pisano Wayne	Director	Jan 08 '26	Buy	4.08	5,000	20,410	13,498	Jan 09 04:10 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '26	Option Exercise	0.00	9,375	0	45,645	Jan 05 04:10 PM
Jorkasky Diane	Director	Dec 29 '25	Buy	3.80	527	2,003	527	Dec 29 04:10 PM
GILL JOHN	Director	Dec 23 '25	Buy	4.10	12,500	51,250	12,500	Dec 23 04:10 PM
Durso Jerome Benedict	Director	Dec 22 '25	Buy	4.13	12,500	51,569	12,500	Dec 22 04:10 PM
WEAVER GREGORY L	Chief Financial Officer	Nov 11 '25	Option Exercise	0.00	18,750	0	28,750	Nov 12 04:07 PM
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM
Garg Vipin K	President and CEO	Feb 02 '25	Option Exercise	0.00	18,950	0	363,364	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Feb 01 '25	Option Exercise	0.00	16,545	0	351,645	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Jan 30 '25	Option Exercise	0.00	26,775	0	342,696	Feb 03 08:50 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	84,564	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	78,898	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	74,000	Feb 03 08:48 PM
Roberts M Scot	Chief Scientific Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	75,536	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	69,562	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	62,921	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	57,910	Jan 28 09:06 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	36,150	Jan 28 09:05 PM
Harris Matthew Scott	Chief Medical Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	69,719	Jan 28 09:05 PM
Garg Vipin K	President and CEO	Jan 25 '25	Option Exercise	0.00	42,050	0	334,078	Jan 28 09:04 PM

MAZE

Maze Therapeutics Inc

ALT

Altimmune Inc

Upgrade your FINVIZ experience